|
KMID : 1141720160040010005
|
|
폐쇄성폐질환
2016 Volume.4 No. 1 p.5 ~ p.5
|
|
|
|
|
Min Kyung-Hoon
|
|
|
Abstract
|
|
|
|
Inhaled corticosteroids (ICS) are commonly prescribed for patients with chronic obstructive airway diseases such as bronchial asthma and severe chronic obstructive pulmonary disease. Although their use improves quality of life and reduces exacerbations in chronic obstructive pulmonary disease, it is associated with increased risk of pneumonia. The risk of pneumonia is associated with types of ICS, duration of use of ICS, and doses of ICS. However, all current studies find either no difference or a reduction in pulmonary-related mortality associated with the use of ICS. Clinicians should be evaluated as a balance between the benefits and the risks of ICS use for an individual patient with chronic obstructive pulmonary disease.
|
|
|
KEYWORD
|
|
|
Chronic obstructive lung disease, Inhaled corticosteroids, Pneumonia, Pneumonia related mortality
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|